GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-31. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
== Mechanism of action == Recently, it has been shown that trabectedin blocks DNA binding of the oncogenic transcription factor FUS-CHOP and reverses the transcriptional program in myxoid liposarcoma. By reversing the genetic program created by this transcription factor, trabectedin promotes differentiation and reverses the oncogenic phenotype in these cells. Other than transcriptional interference, the mechanism of action of trabectedin is complex and not completely understood. The compound is known to bind and alkylate DNA at the N2 position of guanine. It is known from in vitro work that this binding occurs in the minor groove, spans approximately three to five base pairs and is most efficient with CGG sequences. Additional favorable binding sequences are TGG, AGC, or GGC. Once bound, this reversible covalent adduct bends DNA toward the major groove, interferes directly with activated transcription, poisons the transcription-coupled nucleotide excision repair complex, promotes degradation of RNA polymerase II, and generates DNA double-strand breaks. In 2024, researchers from ETH Zürich and UNIST determined that abortive transcription-coupled nucleotide excision repair of trabectedin-DNA adducts forms persistent single-strand breaks (SSBs) as the adducts block the second of the two sequential NER incisions. The researchers mapped the 3’-hydroxyl groups of SSBs originating from the first NER incision at trabectedin lesions, recording TC-NER on a genome-wide scale, which resulted in a TC-NER-profiling assay TRABI-Seq.
In July 2006, according to the New York Times, unpublished e-mails from FDA safety official David Graham argued telithromycin had not been proven safe, that safer drugs were available for the same indications, and that the approval was a mistake and should be immediately withdrawn. Between the start of telithromycin's marketing in mid-2004 and September 2006, there were 13 cases of liver failure, including at least four deaths, vision problems, blackouts, syncope, and potentially fatal cases of myasthenia gravis. The Times said that the FDA was embroiled in a "fierce battle" over the approval, fueled by exposure in the press. Senator Charles E. Grassley (R-Iowa, chairman, Senate Finance Committee), Representatives Edward J. Markey (D-Mass) and Henry A. Waxman (D-Calif) held hearings.
=== Burn and wound healing center === Edlich's interest in emergency medical care was complemented by his clinical experience in burn care. After accepting the position as Director of University of Virginia Burn Center, which initially consisted of only two beds, he enlisted the help of benefactors as well as the University of Virginia to develop the 16-bed DeCamp Burn and Wound Healing Center, which included a hyperbaric oxygen treatment system for patients with necrotizing fasciitis and purpura fulminans. He helped to devise a new silver sulfadiazine cream containing poloxamer 188 that exhibits less tissue toxicity than that of the commercially available silver sulfadiazine cream. Edlich devised a new Gram stain technique for quantitative bacteriology using stable iodophors rather than unstable aqueous iodine. This reliable Gram stain technique is now being used throughout the world. When Edlich treated burn patients in which the patient's ignited clothing was adherent to the burned skin, he was concerned that the adult textiles were highly flammable and became the ignition source for the burn injury. His clinical measurements of fabric flammability of the textiles as well as a careful review of the ignition source documented that flammable liquids, such as gasoline, were the ignition sources of most burn injuries. Consequently, Edlich initiated a nationwide educational program that has dramatically reduced the frequency of burn injuries stemming from flammable liquids.
In vitro, VPg-RNA conjugates were translated with similar efficiency to m7G-capped RNAs indicating that VPg binds eIF4E and engages the translation machinery; while free VPg (in the absence of conjugated RNA) successfully competes for all the cap-dependent activities of eIF4E in the cell inhibiting translation and RNA export.
Sources: en.wikipedia.org
Hemoglobin H disease, also called α-thalassemia intermedia, is a disease affecting hemoglobin, the oxygen carrying molecule within red blood cells. It is a form of α-thalassemia which most commonly occurs due to deletion of 3 out of 4 of the α-globin genes.
Hemodiafiltration is a combination between hemodialysis and hemofiltration, thus used to purify the blood from toxins when the kidney is not working normally and also used to treat acute kidney injury (AKI).
Since 2007, Israel had implemented a strict land and sea blockade that had prevented items such as food and medicine from moving into the Gaza Strip, with the health system struggling before the war. Ahmed al-Fara, the head of pediatrics at Nasser Medical Complex in Khan Younis, stated due to the lack of water during the war, he was witnessing the "most serious epidemic of gastroenteritis" among children he had ever seen. Catherine M. Russell, the executive director of UNICEF, toured Gaza on 15 November 2023, stating many children were lacking medical care. On 28 December, UNOCHA stated 50 percent of all children in the Gaza Strip were experiencing dehydration, malnutrition, respiratory and skin diseases. Cases of diarrhea in children under the age of five has increased by about 2,000% since 7 October per a UNICEF report. A UN spokesperson indicated that between 7 October 2023 and 4 January 2024, disease had skyrocketed in Gaza with more than 400,000 cases of infectious disease reported, which included about 180,000 people with upper respiratory infections and more than 136,000 cases of diarrhea, with half of cases presenting in children under 5. By July 2024, WHO stated more than 150,000 people had contracted skin infections, with malnourished children most susceptible due to their weakened immune systems. According to statistics published by the World Health Organization (WHO), in January 2024, only about 30% of medics were still working due to the widespread effects of the war in Gaza.
There are a few slightly more common diagnoses such as pulmonary hypoplasia, cryptorchidism, congenital heart defects, tracheoesophageal fistulas, inguinal hernias, cleft palate, and eye abnormalities.
The IQOS is a heated tobacco product marketed by Philip Morris International. It heats tobacco at a lower temperature than traditional cigarettes. The tobacco sticks reach a temperature up to 350 °C. It sold first in Japan since November 2014. In December 2016, the United Tobacco Vapor Group's (UTVG) stated that they have been given a patent for their vaporizing component system. QMOS from UTVG does not contain a wick or sponge and the number of components is 5 compared to 20 for traditional e-cigarettes. Pax Labs has developed vaporizers that heats the leaves of tobacco to deliver nicotine in a vapor. In June 2015, they introduced Juul, a type of e-cigarette which delivers 10 times as much nicotine as other e-cigarettes, equivalent to an actual cigarette puff. Juul was spun off from Pax Labs in June 2017 and is now available by the independent company Juul Labs. The eTron 3T from Vapor Tobacco Manufacturing, launched in December 2014, employs a patented, aqueous system whereby the tobacco is extracted into water. The e-liquid contains organic tobacco, organic glycerin, and water. In December 2013, Japan Tobacco launched Ploom in Japan. In January 2016, they launched Ploom TECH that produces a vapor from a heated liquid that moves through a capsule of granulated tobacco leaves. In 2016, British American Tobacco (BAT) released its own version of the heat but not burn technology called glo in Japan and Switzerland. It uses tobacco sticks rather than nicotine liquid, and does not directly heat or burn tobacco.
Sources: en.wikipedia.org
The Islamabad Talks, also known as the Islamabad Peace Talks, were held in Islamabad, Pakistan, on 11 and 12 April 2026. Aimed at stabilizing the 2026 Iran war ceasefire and negotiating a potential resolution to the war, the talks were moderated by Pakistan, which played a central role in brokering the ceasefire and facilitating the talks. The 300-member U.S. negotiating team was led by Vice President JD Vance, alongside special envoys Steve Witkoff and Jared Kushner; while the 70-member Iranian team was led by parliamentary speaker Mohammad Bagher Ghalibaf, alongside foreign minister Abbas Araghchi. The Pakistani mediating team was led by prime minister Shehbaz Sharif, field marshal Asim Munir, and deputy prime minister and foreign minister Ishaq Dar. The talks lasted 21 hours between 11 and 12 April 2026, and consisted of three rounds with the first one being indirect and the second and third ones being direct. The day of the meeting, Trump told reporters that he did not care about whether an agreement would come out of the talks. The teams were reportedly able to agree on the main points of the 10-points ceasefire, with the exception of the issues regarding the Strait of Hormuz and the Iranian nuclear program. The talks ended with no agreement reached, and no memorandum of understanding (MoU) being issued. Following the failure of the talks, U.S. president Donald Trump imposed a naval blockade on Iran on 13 April, interdicting any ships entering or departing Iranian ports.
== External links == Official website (Archived) Theranos Original Pitchdeck 2006, "A Presentation for Investors" "Elizabeth Holmes on Her Billion-Dollar Health Care Idea", Charlie Rose via YouTube, June 3, 2015. Tobak, Steve, "After the Theranos Mess, Can We Finally Quit Idolizing Entrepreneurs?" (Commentary), Fortune magazine. May 27, 2016. "Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud" (Press release). The Securities and Exchange Commission. Retrieved March 14, 2018. Theranos' Fatal Flaws Were in Plain Sight, Barry Ritholz. Bloomberg Opinion. 31 May 2018. The Rise and Fall of Elizabeth Holmes, Avery Hartmans. Business Insider Australia. April 21, 2018.
== Risk factors == End organ dysfunction (liver disease), which may lead to decreased drug clearance, is a risk factor for opioid overdose. Other risk factors for opioid overdose include sleep disordered breathing disorders such as sleep apnea, pulmonary diseases (such as asthma or chronic obstructive pulmonary disease) which may reduce ventilation and concomitant use of sedating medications such as benzodiazepines, gabapentinoids, muscle relaxants and other central nervous system depressants. Benzodiazepine use with opioids increases the risk of overdose death by four-fold, whereas concomitant use with gabapentintoids such as gabapentin or pregabalin increases the risk of overdose death by nearly two-fold. Higher doses of prescription opioids, as well as long-acting formulations, are associated with an increased risk of overdose. In those on long-term opioid treatment for chronic pain, daily morphine equivalents greater than 200 mg were associated with death from opioid related causes (including overdose) in 3.8% of men and 2.2% of women. Opioids are the most common cause for serious accidental poisonings of children in the UK.
Synthesis of pharmaceuticals, flavors and fragrances, agrochemicals, nutraceuticals, fine chemicals, bulk monomers and biofuels. Animal feed, e.g. phytase for utilization of organically bound phosphate by pigs and poultry. Food and beverage processing, e.g. lipases in cheese manufacture and laccase in wine clarification. Cosmetics, e.g. in skin care products Oils and fats processing, e.g. in biolubricants, bioemulsifiers, bio-derived emollients. Carbohydrate processing, e.g. laccase in carbohydrate oxidations. Pulp and paper, e.g. in pulp bleaching. Detergents, e.g. proteases, amylases and lipases for removal of protein, carbohydrate and fat stains. Waste water treatment, e.g. for removal of phenols, dyes, and endocrine disrupters. Biosensors/diagnostics, e.g. glucose oxidase and cholesterol oxidase biosensors. Delivery of proteins as therapeutic agents or nutritional/digestive supplements e.g. beta-galactosidase for digestive hydrolysis of lactose in dairy products to alleviate the symptoms of lactose intolerance.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.